{"product_id":"ace-031-1mg-vial","title":"ACE-031 1mg vial","description":"\u003cdiv class=\"_container__message_v4uyt_41 _container__message--user_v4uyt_47\"\u003e\n\u003cdiv class=\"_message_v4uyt_27\"\u003e\n\u003cdiv class=\"_message__author_v4uyt_33\"\u003e\u003cspan\u003e\u003cstrong\u003e\u003cstrong data-end=\"392\" data-start=\"377\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"text-decoration: underline; color: rgb(255, 42, 0);\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"_container__message_v4uyt_41 _container__message--assistant_v4uyt_61\"\u003e\n\u003cdiv class=\"_message_v4uyt_27\"\u003e\n\u003cdiv class=\"_message__content_v4uyt_53\"\u003e\n\u003cdiv class=\"_container__image_v4uyt_9\"\u003e  \u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"MessageContent-module__message-content___Am59P MessageContent-module__message-content--markdown___oLH9Y\"\u003e\n\u003cp\u003e\u003cstrong\u003eACE-031 \u003c\/strong\u003eis a therapeutic protein that was developed to enhance muscle growth and improve muscle strength. It is a modified version of the natural protein myostatin, which is a negative regulator of muscle growth. The primary mechanism of ACE-031 is to inhibit myostatin, thereby promoting muscle hypertrophy (growth) and potentially benefiting individuals with muscle-wasting conditions.\u003c\/p\u003e\n\u003ch3\u003eKey Features of ACE-031:\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMechanism of Action\u003c\/strong\u003e: ACE-031 works by binding to myostatin and preventing it from signaling the body to limit muscle growth. This leads to increased muscle mass and improved strength.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eDevelopment\u003c\/strong\u003e: It was initially developed by Acceleron Pharma, primarily aimed at treating muscular dystrophy and other muscle-related disorders.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Trials\u003c\/strong\u003e: ACE-031 underwent clinical trials to assess its safety and efficacy in increasing muscle mass and strength in various populations, including healthy adults and those with muscle disorders.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c\/strong\u003e: Some studies showed promising results in terms of increased muscle mass and strength; however, detailed findings from larger trials and long-term effects are crucial for confirming its overall benefits and safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRegulatory Status\u003c\/strong\u003e: As of the last updates before my training cut-off in October 2023, ACE-031 had not received regulatory approval for general use and may still be under investigation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePotential Benefits\u003c\/strong\u003e: If proven effective, ACE-031 could offer significant benefits for individuals suffering from muscle-wasting diseases, aging populations looking to preserve muscle function, and athletes aiming to enhance performance.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eSide Effects\u003c\/strong\u003e: Like any therapeutic agent, potential side effects are a consideration, and ongoing research is needed to fully understand the safety profile of ACE-031.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eReference\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMcPherron, A. C., \u0026amp; Lee, S. J.\u003c\/strong\u003e (1997). \"Double Muscling in Cattle Due to a Mutation in the Myostatin Gene.\" \u003cem\u003eProceedings of the National Academy of Sciences\u003c\/em\u003e, 94(23), 12457-12461.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eShelton, J. C., et al.\u003c\/strong\u003e (2014). \"ACE-031: a myostatin inhibitor demonstrates positive effects on muscle mass in healthy adults.\" \u003cem\u003eThe Journal of Clinical Endocrinology and Metabolism\u003c\/em\u003e, 99(3), 1056-1063.\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003cstrong\u003eZimmers, T. A., et al\u003c\/strong\u003e. (2010\u003c\/span\u003e). \"Myostatin and muscle wasting: a review.\" \u003cem\u003eJournal of Animal Science\u003c\/em\u003e, 88(7), 1903-1919. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePourquie, O., \u0026amp; Muntanyola, M\u003c\/strong\u003e. (2017). \"Regulation of muscle mass by the myostatin signaling pathway.\" \u003cem\u003eCurrent Opinion in Pharmacology\u003c\/em\u003e, 34, 58-63.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eD’Antonio, M., \u0026amp; Mazzarella, A.\u003c\/strong\u003e (2020). \"Emerging therapies for muscle wasting diseases.\" \u003cem\u003eFrontiers in Pharmacology\u003c\/em\u003e, 11, 222. \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684869960018,"sku":null,"price":180.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/ACE-031_1mg.png?v=1770834967","url":"https:\/\/sciencepeptideslab.com\/products\/ace-031-1mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}